BYD Europe Challenges Tesla, EU Giants; Stellantis Defends Italian Turf 
Kakao Thrives Amidst Chinese E-commerce Expansion in Korea 
Samsung Follows Apple, Abandons Autonomous Driving and EV Research Initiatives 
Samsung Galaxy S24 Boosts Sales, Reaches Four-Year High in Q1 2024 Smartphone Market 
Kith and ASICS Gear Up for an Exclusive Sneaker Launch Inspired by South Korea 
South Korea Backs Naver in Business Rift with Japan Over Line App 
USAID and The Coca-Cola Foundation Launch Initiative to Combat Plastic Waste in Nigeria 
Burger King Announces Grand Whopper Giveaway for Mother’s Day; Free Items Until June 
PUMA Unveils 'Be You' Edition of the MB.03 Before Launching LaMelo Ball's Newest MB.04 Sneaker 
SEC Opens Investigation into Boeing Co. over Safety Statements 
McDonald’s Sets Up Digital Marketing Fund to Introduce New Ordering Channels, Loyalty Program 
PepsiCo Aims to Make Its Spain Plant the First Facility to Reach Net-Zero Emissions 
Ford Revises Europe Strategy, Considers Gas and Hybrid Options Beyond 2030 
Novavax, Sanofi Ink Deal to Commercialize COVID-19 Vaccine to Jointly Produce Combination Shots 
Divesting university endowments: Easier demanded than done 
NEW YORK, April 05, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased PTC Therapeutics, Inc. (NASDAQ:PTCT) securities between May 7, 2014 and February 29, 2016.
Click here to learn about the case: http://docs.wongesq.com/PTCT-Info-Request-Form-1135. There is no cost or obligation to you.
The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements, and omitted materially adverse facts, about the Company’s business, operations and prospects. According to the Complaint, on February 23, 2016, PTC announced that it received a Refuse to File letter from the United States Food and Drug Administration (“FDA”) regarding the New Drug Application for Translarna. The FDA stated in the Refuse to File letter that the application was not sufficiently complete to permit a substantive review. On this news, shares of PTC fell over 61%, closing at $10.84 per share on February 23, 2016, on heavy trading volume.
If you suffered a loss in PTC you have until May 2, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/PTCT-Info-Request-Form-1135.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigation involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
